Towards government-funded special biomedical research programs to combat rare diseases in China

BioScience Trends

Volumn 9, Issue 2, 2015, Pages 88-90

  Chen, Kai ^a   Yao, Lan ^a   Liu, Zhiyong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Medical care; Orphan drugs; Public health; Rare diseases

Indexed keywords

CHINA; ECONOMICS; EUROPEAN UNION; FINANCIAL MANAGEMENT; HUMAN; JAPAN; MEDICAL RESEARCH; RARE DISEASES; TRENDS; UNITED STATES;

BIOMEDICAL RESEARCH; CHINA; EUROPEAN UNION; FINANCING, GOVERNMENT; HUMANS; JAPAN; RARE DISEASES; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 84929611892     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2015.01048     Document Type: Article

References (16)

1. Rare Diseases Europe. Rare Disease Day 2015. http://www.rarediseaseday.org (accessed March 20, 2015).
2. The Lancet Neurology. The bucket list for amyotrophic lateral sclerosis. Lancet Neurol. 2014; 13:1061.
3. Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens S, Pani L, Garattini S, Remuzzi G. Rare diseases and effective treatments: Are we delivering? Lancet. 2015; 385:750-752.
4. Stolk P, Willemen MJ, Leufkens HG. Rare essentials: Drugs for rare diseases as essential medicines. Bull World Health Organ. 2006; 84:745-751.
5. Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet. 2008; 371:2039-2041.
6. O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: Will the market bear what society cannot? JAMA. 2013; 310:1343-1344.
7. Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S. Market uptake of orphan drugs-a European analysis. J Clin Pharm Ther. 2012; 37:664-667.
8. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res 2012; 1:3-9.
9. Remuzzi G, Garattini S. Rare diseases: What's next? Lancet. 2008; 371:1978-1979.
10. WästfeltM, Fadeel B, Henter JI. A journey of hope: Lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006; 260:1-10.
11. Bayrakli F, Erkek E, Kurtuncu M, Ozgen S. Intraventricular hemorrhage as an unusual presenting form of Sneddon syndrome. World Neurosurg. 2010; 73:411-413.
12. Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet. 2008; 372:889-890.
13. The Ministry of Health, Labour and Welfare. The Results of Early Exploratory Clinical Trial Bases for Specific Research Areas. http://www.mhlw.go.jp/stf/houdou/2r9852000001jym4.html (accessed March 21, 2015).
14. The Japanese Ministry of Health, Labor, and Welfare. Reform of measures to combat intractable diseases. http://www.mhlw.go.jp/stf/shingi/2r9852000002n6roatt/2r9852000002n6uj.pdf (accessed February 15, 2015). (in Japanese).
15. Wang JB, Guo JJ, Yang L, Zhang YD, Sun ZQ, Zhang YJ. Rare diseases and legislation in China. Lancet. 2010; 375:708-709.
16. Ding JX, Sun XD, Ji N, Shao WJ. The accessibility assessment on orphan drugs and legal system research in China and America. Chinese Pharmaceutical Journal. 2011; 46:1129-1132. (in Chinese).